SCHEMBL1198348

SCHEMBL1198348

O=C(O)c1cnn(Cc2nc(-c3cccc(C(F)(F)F)c3)sc2C(F)(F)F)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
MEN1 O00255 4/20 0.48
KMT2A Q03164 4/20 0.48
NPC1 O15118 1/20 0.48
RAB9A P51151 1/20 0.48
EGLN1 Q9GZT9 3/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPT P10636 2/20 0.42
KCNH2 Q12809 1/20 0.42
S1PR1 P21453 1/20 0.42
S1PR3 Q99500 1/20 0.42
LIPG Q9Y5X9 1/20 0.41
ALPL P05186 1/20 0.39
ALPI P09923 1/20 0.39
CFTR P13569 1/20 0.39
ADORA2A P29274 1/20 0.39
ADORA2B P29275 1/20 0.39
ADORA1 P30542 1/20 0.39
KMO O15229 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1198880 0.89 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198840 0.89 ALDH1A1 (0.53) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198722 0.89 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198826 0.89 KMT2A (0.48) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198021 0.88 MAPT (0.56) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198292 0.88 ALDH1A1 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198412 0.88 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1199154 0.86 MEN1 (0.46) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198136 0.83 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1
SCHEMBL1198845 0.82 MEN1 (0.47) ALDH1A1SMN1; SMN2MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8461348-B2 Heterocyclic derivative and use thereof TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-06-11 US disclosed
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-02-03 US disclosed
EP-2264017-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2010-12-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110028493-A1 HETEROCYCLIC DERIVATIVE AND USE THEREOF PDE3B, PDE5A, PDE2A ALDH1A1 1037/4885SMN1; SMN2 2057/4885MEN1 2661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.